Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Blood

• Publication date

  1995-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/BLOOD.V86.9.3287.BLOODJOURNAL8693287PMID 7579429
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study.

  1995cited by this paper
• Viral dynamics in human immunodeficiency virus type 1 infection

  1995cited by this paper
• Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

  1995cited by this paper
• Low-dose interleukin 2 prevents the development of Epstein-Barr virus (EBV)-associated lymphoproliferative disease in scid/scid mice reconstituted i.p. with EBV-seropositive human peripheral blood lymphocytes.

  1994cited by this paper
• The development of anti-interleukin-2 (IL-2) antibodies in cancer patients treated with recombinant IL-2.

  1994cited by this paper
• Innate immunity: 50 ways to kill a microbe.

  1994cited by this paper
• Anergy and apoptosis in CD8+ T cells from HIV-infected persons.

  1994cited by this paper
• Cytokine patterns during the progression to AIDS.

  1994cited by this paper
• Cell preparation for the identification of leukocytes.

  1994cited by this paper
• Lack of evidence for the dichotomy of TH1 and TH2 predominance in HIV-infected individuals.

  1994cited by this paper
• Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma.

  1994cited by this paper
• Elevated IFN-gamma and decreased IL-2 gene expression are associated with HIV infection.

  1993cited by this paper
• Multifactorial nature of human immunodeficiency virus disease: implications for therapy.

  1993cited by this paper
• The spectrum of acquired immunodeficiency syndrome (AIDS)-associated malignancies in San Francisco, 1980-1987.

  1993cited by this paper
• The role of natural killer cells in innate resistance to infection.

  1993cited by this paper
• The immunopathogenesis of human immunodeficiency virus infection.

  1993cited by this paper
• Accessory cell function of human eosinophils. HLA-DR-dependent, MHC-restricted antigen-presentation and IL-1 alpha expression.

  1993cited by this paper
• Human immunodeficiency virus‐related lymphoma. Prognostic factors predictive of survival

  1991cited by this paper
• Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity.

  1991cited by this paper
• Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors

  1990cited by this paper
• Interleukin-2: inception, impact, and implications.

  1988cited by this paper
• Detection of HIV-1 RNA sequences by in vitro DNA amplification.

  1988cited by this paper
• Survival with the acquired immunodeficiency syndrome. Experience with 5833 cases in New York City.

  1987cited by this paper
• Biological and biochemical characterization of a cloned Leu-3- cell surviving infection with the acquired immune deficiency syndrome retrovirus

  1986cited by this paper

• Fine-tuned long-acting interleukin-2 superkine potentiates durable immune responses in mice and non-human primate

  2022cites this paper
• Immunology of EBV-Related Lymphoproliferative Disease in HIV-Positive Individuals

  2020cites this paper
• Harnessing Natural Killer Cells’ Killing Function in Cancer

  2020cites this paper
• Low‐dose IL‐2 induces CD56bright NK regulation of T cells via NKp44 and NKp46

  2020cites this paper
• NK cells to cure cancer.

  2019cites this paper
• Immune Escape after Hematopoietic Stem Cell Transplantation (HSCT): From Mechanisms to Novel Therapies

  2019cites this paper
• Co-stimulation of the fc receptor and interleukin-12 receptor on human natural killer cells leads to increased expression of cd25

  2018cites this paper
• Immunomodulatory activity of Neolamarckia cadamba (Roxb.) Bosser with reference to IL-2 induction

  2018cites this paper
• Chapter 22 – Natural Killer Cell Immunity

  2018cites this paper
• Upregulation of thioredoxin-1 in activated human NK cells confers increased tolerance to oxidative stress

  2017cites this paper
• Utilizing Cytokines to Function-Enable Human NK Cells for the Immunotherapy of Cancer

  2014cites this paper
• Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy.

  2014cites this paper
• expansion, and maturation of mouse natural killer cells The receptor tyrosine kinase c-kit provides a critical signal for survival,

  2013cites this paper
• Optimisation d’une stratégie thérapeutique antitumorale conventionnelle par association à une immunothérapie : etude de phase I combinant l’Imatinib à l’Interleukine-2

  2013cites this paper
• Phase I clinical trial combining imatinib mesylate and IL-2

  2013cites this paper
• Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs β-Cell Function

  2012cites this paper
• Exploiting the Interplay between Innate and Adaptive Immunity to Improve Immunotherapeutic Strategies for Epstein-Barr-Virus-Driven Disorders

  2012cites this paper
• Modulation of Human Immune Responses by Bovine Interleukin-10

  2011cites this paper
• Immunomodulating property of Ocimum sanctum by regulating the IL-2 production and its mRNA expression using rat's splenocytes

  2010cites this paper
• Interleukin-2 for Nonmelanoma Skin Cancer

  2010cites this paper
• Potential for Immune Reconstitution through G-CSF Treatment of HIV Patients

  2009cites this paper
• Natural killer cell‐based immunotherapy in cancer: current insights and future prospects

  2009cites this paper
• Effect of Low-Dose IL-2 Immunotherapy on Frequency and Phenotype of Regulatory T Cells and NK Cells in HIV/HCV-Coinfected Patients

  2008cites this paper
• Human natural killer cell development and biology.

  2006cites this paper
• Immunologic approaches to acute leukemia in the elderly.

  2006cites this paper
• A Phase I Study of Ultra Low Dose Interleukin-2 and Stem Cell Factor in Patients with HIV Infection or HIV and Cancer

  2006cites this paper
• The Therapeutic Use of Natural-Killer Cells in Hematological Malignancies

  2006cites this paper
• Maintenance biotherapy with interleukin-2 and interferon for metastatic renal cell cancer

  2006cites this paper
• APhase I Study of Ultra Low Dose Interleukin-2 and Stem Cell Factor in Patients with HIV Infection or HIVand Cancer

  2006cites this paper
• Interleukin-2, interleukin-15, and their roles in human natural killer cells.

  2005cites this paper
• IL-15: targeting CD8+ T cells for immunotherapy.

  2005cites this paper
• Combination Immunotherapy of B-Cell Non-Hodgkin’s Lymphoma with Rituximab and Interleukin-2

  2004cites this paper
• Cytokine modulation of the innate immune system in the treatment of leukemia and lymphoma.

  2004cites this paper
• Therapeutic HER2/Neu DNA vaccine inhibits mouse tumor naturally overexpressing endogenous neu.

  2004cites this paper
• Interleukin-2 for the Treatment of HIV Infection

  2003cites this paper
• Biology and clinical impact of human natural killer cells

  2003cites this paper
• HIV, 'an evolving species'. Roles of cellular activation and co-infections.

  2003cites this paper
• Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial)

  2002cites this paper
• Sustained Suppression of HCV Replication and Inflammatory Activity After Interleukin‐2 Therapy in Patients With HIV/Hepatitis C Virus Coinfection

  2002cites this paper
• New targets for the treatment of advanced non-small cell lung cancer.

  2002cites this paper
• Tumor necrosis factor alpha, interleukin 2, and soluble interleukin 2 receptor levels in human immunodeficiency virus type 1-infected individuals receiving intermittent cycles of interleukin 2.

  2002cites this paper
• Retrospective analysis of HHV-8 viremia and cellular viral load in HIV-seropositive patients receiving interleukin 2 in combination with antiretroviral therapy.

  2002cites this paper
• Potential for immune reconstitution through G-CSF treatment of HIV patients.

  2002cites this paper
• Tumor Necrosis Factor α, Interleukin 2, and Soluble Interleukin 2 Receptor Levels in Human Immunodeficiency Virus Type 1-Infected Individuals Receiving Intermittent Cycles of Interleukin 2

  2002cites this paper
• Mechanisms of endogenous and therapeutic immune modulation by G-CSF

  2002cites this paper
• Interleukin-2 and interleukin-15: immunotherapy for cancer.

  2002cites this paper
• Melatonin and the Immune System Therapeutic Potential in Cancer, Viral Diseases, and Immunodeficiency States

  2001cites this paper
• Long‐term immunotherapy with low‐dose interleukin‐2 and interferon‐α in the treatment of patients with advanced renal cell carcinoma

  2001cites this paper
• Cytokines and Chemokines in HIV Infection

  2001cites this paper
• HIV-Associated lymphomas

  2001cites this paper
• Ontogeny and Expansion of Human Natural Killer Cells: Clinical Implications

  2001cites this paper
• Interleukin 15: biology and relevance to human disease.

  2001cites this paper
• La melatonina: ¿un posible agente terapéutico?

  2001cites this paper
• Acquired immunodeficiency syndrome-related lymphomas: future directions.

  2000cites this paper
• Effects of Subcutaneous Interleukin‐2 Therapy on Phenotype and Function of Peripheral Blood Mononuclear Cells in Human Immunodeficiency Virus Infected Patients

  2000cites this paper
• Natural And Induced Anticytokine Antibodies In Humans

  2000cites this paper
• Non–Hodgkin’s Lymphoma

  2000cites this paper
• A Risk-Benefit Assessment of Interleukin-2 as an Adjunct to Antiviral Therapy in HIV Infection

  2000cites this paper
• Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy.

  2000cites this paper
• Interleukin-2 in Cancer Therapy

  2000cites this paper
• Cytokine replacement in patients with HIV-1 non-Hodgkin's lymphoma: the rationale for low-dose interleukin-2 therapy.

  2000cites this paper
• Immune-Based Therapies for the Management of HIV Infection: Highly Active Antiretroviral Therapy and Beyond

  2000cites this paper
• Subcutaneous Interleukin-2 in Combination with Anti-retroviral Therapy for Treatment of HIV-1-Infected Subjects

  2000cites this paper
• Low prevalence of antibodies and other plasma factors binding to CC chemokines and IL‐2 in HIV‐positive patients

  2000cites this paper
• The receptor tyrosine kinase c-kit provides a critical signal for survival, expansion, and maturation of mouse natural killer cells.

  2000cites this paper
• Immune system activation by CDDP and "poly-plat".

  2000cites this paper
• Thrombopoietic cytokines in relation to platelet recovery after bone marrow transplantation

  2000cites this paper
• Pulmonary Malignancies in the Immunocompromised Patient

  1999cites this paper
• Anti-Inflammatory Aspects of Filgrastim and Impact on IL-2 Release

  1999cites this paper
• Chemokine immunobiology in HIV‐1 pathogenesis

  1999influential citation
• Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response.

  1999cites this paper
• AIDS-associated lymphoma.

  1999cites this paper
• Cytokines in the evolution and treatment of AIDS-lymphoma.

  1999cites this paper
• Treatment of AIDS-Related Primary Central Nervous System Lymphoma with Zidovudine, Ganciclovir, and Interleukin 2

  1999cites this paper
• Immune Reconstitution: Is There a Potential Role for Filgrastim (r-metHuG-CSF)?

  1999cites this paper
• MLT and the immune-hematopoietic system.

  1999cites this paper
• Innate Immune Response Combination with IL-12: Implications for the Activation with IL-18 or IL-15 in Expression by Human NK Cells Following Differential Cytokine and Chemokine Gene

  1999cites this paper
• This information is current as Infection Produce C-C Chemokines and Inhibit HIV-1 Patients + Natural Killer Cells from HIV-1

  1998cites this paper
• AIDS-related malignancies.

  1998cites this paper
• Natural killer cells from HIV-1+ patients produce C-C chemokines and inhibit HIV-1 infection.

  1998cites this paper
• The photoperiod transducer melatonin and the immune-hematopoietic system.

  1998cites this paper
• Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies.

  1998cites this paper
• Filgrastim restores interleukin-2 production in blood from patients with advanced human immunodeficiency virus infection.

  1998cites this paper
• In vitro enhancement of T-cell receptor-targeted lysis after IL-2 treatment of PBL from HIV-seropositive individuals.

  1998cites this paper
• Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing

  1998cites this paper
• Clinical management of human immunodeficiency virus-associated non-Hodgkin's lymphoma.

  1998cites this paper
• Clinical Management of Human Immunodeficiency Virus-Associated Non-Hodgkin's Lymphoma

  1998cites this paper
• Lymphomas in the immunocompromised patient.

  1998cites this paper
• Use of Interleukin-2 in Immunotherapy of Human Immunodeficiency Virus Infection

  1998cites this paper
• Endogenous interleukin-2 serum levels in children infected with human immunodeficiency virus.

  1997cites this paper
• How Does Basic Research in Cancer and AIDS Approach the Concern for Quality of Life

  1997cites this paper
• Serum Levels of Thrombopoietin in Health and Disease

  1997cites this paper
• Use of hematopoietic hormones for bone marrow defects in AIDS.

  1997cites this paper
• Phenotypic and functional analysis of Fas (CD95) expression in primary central nervous system lymphoma of patients with acquired immunodeficiency syndrome.

  1997cites this paper
• Subcutaneous versus intravenous low-dose IL-2 therapy after autologous transplantation: results of a prospective, non-randomized study

  1997cites this paper
• Human immunodeficiency virus-associated lymphomas.

  1997cites this paper
• Stem cell factor enhances interleukin-2-mediated expansion of murine natural killer cells in vivo.

  1997cites this paper
• Differential Effects of Interleukin-12 , Interleukin-15 , and Interleukin-2 on Human Immunodeficiency Virus Type 1 Replication In Vitro

  1996cites this paper
• Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity.

  1996cites this paper
• Melatonin and the immune-hematopoietic system therapeutic and adverse pharmacological correlates.

  1996cites this paper